Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy. Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and Drug Administration-approved treatment for this disease.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and Drug Administration-approved treatment for this disease.
- Ponto de atenção: gene.
- Ponto de atenção: clues.
- Ponto de atenção: reveal.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
